reported as follows: (a) elderly (74-87 years at diagnosis), (b) male, (c) unexpectedly showed no other autoimmune

September 2022 β2-Adrenergic Receptor Expression and Intracellular Signaling in B Cells Are Highly Dynamic during Collagen-Induced Arthritis "The sympathetic nervous system (SNS) has either a pro-inflammatory or anti-inflammatory effect, depending on the stage of arthritis. In the past, treatment of arthritic B cells with a β2-adrenergic receptor (β2-ADR) agonist has been shown to attenuate arthritis. In this study, the expression and signaling of β2-ADR in B cells during collagen-induced arthritis (CIA) were investigated to provide an explanation of why only B cells from arthritic mice are able to improve CIA. Splenic B cells were isolated via magnetic-activated cell sorting (MACS). Adrenergic receptors on B cells and intracellular β2-ADR downstream molecules (G protein-coupled receptor kinase 2 (GRK-2), β-Arrestin 2, p38 MAPK, extracellular signal-regulated kinase 1/2 (ERK1/2) and cAMP response element-binding protein (CREB)) were analyzed at different time points in naïve and arthritic B cells with and without stimulation of β2-ADR agonist terbutaline by flow cytometry. β2-ADR-expressing B cells increase during CIA without a change in receptor density. Moreover, we observed a profound downregulation of GRK-2 shortly after induction of arthritis and an increase in β-Arrestin 2 only at late stage of arthritis. The second messengers studied (p38, ERK1/2 and CREB) followed a biphasic course, characterized by a reduction at onset and an increase in established arthritis. Stimulation of CIA B cells with the β-ADR agonist terbutaline increased pp38 MAPK independent of the timepoint, while pERK1/2 and pCREB were enhanced only in the late phase of arthritis. The phosphorylation of p38 MAPK, ERK1/2 and CREB in the late phase of arthritis was associated with increased IL-10 produced by B10 cells. The change of β2-ADR expression and signaling during sustained inflammation might be an integral part of the switch from pro- to anti-inflammatory action of sympathetic mechanisms in late arthritis." Read more at the source #DrGPCR #GPCR #IndustryNews

Vivo Evaluation of ACT-660602: A Potent and Selective Antagonist of the Chemokine Receptor CXCR3 for Autoimmune seven-transmembrane G-protein-coupled receptor (GPCR) involved in various pathologies, in particular autoimmune

., (NASDAQ: CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune

Promising preclinical data supports the applicability of CB2 activation in autoimmune and inflammatory

Promising preclinical data support the applicability of CB2 activation in autoimmune and inflammatory

and it participates in inflammatory and immune responses that have been found to mediate apoptosis in autoimmune β-arrestin2 and provided an experimental foundation for β-arrestin2 depletion in the treatment of the human autoimmune

autoantibodies targeting GPCRs in various diseases, such as cardiovascular diseases, renal diseases, autoimmune

September 2022 "Systemic sclerosis (SSc) is a systemic autoimmune disease with the key features of inflammation

Binders, Drugs, and more Autoantibodies targeting G protein-coupled receptors: An evolving history in autoimmunity

growth, metabolism, and are also linked to major diseases, such as neuroinflammatory, metabolic and autoimmune

in Oncology and Immunology Germinal Center-Related G Protein-Coupled Receptors in Antibody-Mediated Autoimmune

The chemokine receptor system is implicated in a wide range of inflammatory, autoimmune and infectious

ROS-dependent apoptosis in ovarian cancer cells by targeting PAR-1 G protein-coupled receptors related to autoimmunity

agonists Discovery of the Clinical Candidate IDOR-1117-2520: A Potent and Selective Antagonist of CCR6 for Autoimmune